MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Hirata, Yukihiro ^a   Murai, Noriyuki ^a   Yanaihara, Nozomu ^a   Saito, Misato ^a   Saito, Motoaki ^a   Urashima, Mitsuyoshi ^a   Murakami, Yasuko ^a   Matsufuji, Senya ^a   Okamoto, Aikou ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CGH array; MicroRNA 21; Ovarian clear cell carcinoma; PTEN

Indexed keywords

MICRORNA 21; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; MICRORNA; MIRN21 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ADULT; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME 17Q; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; ENDOMETRIOSIS; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOSS OF FUNCTION MUTATION; LUCIFERASE ASSAY; OVARY CARCINOMA; OVERALL SURVIVAL; PPM1 GENE; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PTEN GENE; REAL TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; UPREGULATION; ADENOCARCINOMA; AGED; CANCER STAGING; CHROMOSOME 17; FOLLOW UP; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOMES, HUMAN, PAIR 17; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; FOLLOW-UP STUDIES; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; PTEN PHOSPHOHYDROLASE;

EID: 84928752251     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-799     Document Type: Article

References (27)

1. Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, Tsuda H, Suzuki M, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Sugiyama T: Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 2006, 94:1369-1374.
2. Nishimura S, Tsuda H, Ito K, Takano M, Terai Y, Jobo T, Kigawa J, Sugiyama T, Yaegashi N, Aoki D: Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas. Int J Gynecol Cancer 2010, 20:220-226.
3. Higashiura Y, Kajihara H, Shigetomi H, Kobayashi H: Identification of multiple pathways involved in the malignant transformation of endometriosis (Review). Oncol Lett 2012, 4:3-9.
4. Tan DS, Kaye S: Ovarian clear cell adenocarcinoma: a continuing enigma. J Clin Pathol 2007, 60:355-360.
5. Yokota N, Koizume S, Miyagi E, Hirahara F, Nakamura Y, Kikuchi K, Ruf W, Sakuma Y, Tsuchiya E, Miyagi Y: Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells. Br J Cancer 2009, 101:2023-2029.
6. Lee YY, Kim TJ, Kim MJ, Kim HJ, Song T, Kim MK, Choi CH, Lee JW, Bae DS, Kim BG: Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis. Gynecol Oncol 2011, 122:541-547.
7. Jones S, Wang TL, Shih IM, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N: Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010, 330:228-231.
8. Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, Ohki M, Yasugi T, Taketani Y, Hirohashi S: Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 2003, 163:2503-2512.
9. Hirasawa A, Saito-Ohara F, Inoue J, Aoki D, Susumu N, Yokoyama T, Nozawa S, Inazawa J, Imoto I: Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res 2003, 9:1995-2004.
10. Tan DS, Lambros MB, Rayter S, Natrajan R, Vatcheva R, Gao Q, Marchiò C, Geyer FC, Savage K, Parry S, Fenwick K, Tamber N, Mackay A, Dexter T, Jameson C, McCluggage WG, Williams A, Graham A, Faratian D, El-Bahrawy M, Paige AJ, Gabra H, Gore ME, Zvelebil M, Lord CJ, Kaye SB, Ashworth A, Reis-Filho JS: PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res 2001, 15:2269-2280.
11. Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringe KL, Campbell IG, Australian Ovarian Cancer Study Group, Okamoto A, Birrer MJ, Huntsman DG, de Fazio A, Kalloger SE, Balkwill F, Gilks CB, Bowtell DD: IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res 2011, 17:2538-2548.
12. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
13. Yanaihara N, Harris CC: MicroRNA Involvement in Human Cancers. Clin Chem 2013, 59:1811-1812.
14. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006, 103:2257-2261.
15. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
16. Ho CM, Lin MC, Huang SH, Huang CJ, Lai HC, Chien TY, Chang SF: PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas. Gynecol Oncol 2009, 112:307-313.
17. Hashiguchi Y, Tsuda H, Inoue T, Berkowitz RS, Mok SC: PTEN expression in clear cell adenocarcinoma of the ovary. Gynecol Oncol 2006, 101:71-75.
18. Tan DS, Iravani M, McCluggage WG, Lambros MB, Milanezi F, Mackay A, Gourley C, Geyer FC, Vatcheva R, Millar J, Thomas K, Natrajan R, Savage K, Fenwick K, Williams A, Jameson C, El-Bahrawy M, Gore ME, Gabra H, Kaye SB, Ashworth A, Reis-Filho JS: Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin Cancer Res 2011, 17:1521-1534.
19. Suehiro Y, Sakamoto M, Umayahara K, Iwabuchi H, Sakamoto H, Tanaka N, Takeshima N, Yamauchi K, Hasumi K, Akiya T, Sakunaga H, Muroya T, Numa F, Kato H, Tenjin Y, Sugishita T: Genetic aberrations detected by comparative genomic hybridization in ovarian clear cell adenocarcinomas. Oncology 2000, 59:50-56.
20. Kuo KT, Mao TL, Chen X, Feng Y, Nakayama K, Wang Y, Glas R, Ma MJ, Kurman RJ, Shih IM, Wang TL: DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res 2010, 16:1997-2008.
21. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004, 101:2999-3004.
22. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
23. Lindsey E, Becker B, Yong L: Apoptosis and the target genes of miR-21. Chin J Cancer 2011, 30:371-380.
24. Zhang S, Dihua Y: PI (3) King Apart PTEN's Role in Cancer. Clin Cancer Res 2010, 16:4325-4330.
25. Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager M, Crawford ED, Hsing A, Huang WY, Hayes RB: Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res 2006, 66:4525-4530.
26. Yanaihara N, Anglesio MS, Ochiai K, Hirata Y, Saito M, Nagata C, Iida Y, Takakura S, Yamada K, Tanaka T, Okamoto A: Cytokine gene expression signature in ovarian clear cell carcinoma. Int J Oncol 2012, 41:1094-10100.
27. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K: STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010, 39:493-506.